AMAG - AMAG Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.37
+0.24 (+1.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.13
Open12.00
Bid0.00 x 1100
Ask0.00 x 1800
Day's Range11.79 - 12.39
52 Week Range6.81 - 23.77
Volume549,235
Avg. Volume1,335,910
Market Cap419.352M
Beta (3Y Monthly)0.07
PE Ratio (TTM)N/A
EPS (TTM)-6.83
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.11
Trade prices are not sourced from all markets
  • Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders
    Business Wire

    Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders

    Believes Removal of Four Incumbent Directors is Necessary to Stop Value Destruction at AMAG

  • GlobeNewswire

    AMAG Sends Letter to Shareholders

    WALTHAM, Mass., Sept. 12, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its.

  • Why Is AMAG Pharmaceuticals (AMAG) Up 27.3% Since Last Earnings Report?
    Zacks

    Why Is AMAG Pharmaceuticals (AMAG) Up 27.3% Since Last Earnings Report?

    AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag
    American City Business Journals

    Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag

    The New York firm hopes to replace four of the nine members of Amag’s board with, among others, the former CEO of actress Gwyneth Paltrow’s wellness and lifestyle company Goop, Lisa Gersh.

  • GlobeNewswire

    AMAG Urges Stockholders to Take No Action on Caligan Partners’ Consent Solicitation Materials

    “AMAG regularly engages with shareholders on a range of topics and values their constructive input and is committed to act in the best interest of shareholders to maximize long-term value creation. “AMAG remains open to maintaining a constructive dialogue with Caligan, as it does with all shareholders, about AMAG’s strategy to create sustainable, long-term value.  However, the Company remains steadfast in its belief that any corporate action taken must be for the benefit of all Company shareholders and must be rooted in a strong understanding of the pharmaceutical industry, AMAG’s business and its important milestones ahead.

  • Activist Investor Seek Four Board Seats at Amag Pharmaceuticals
    Bloomberg

    Activist Investor Seek Four Board Seats at Amag Pharmaceuticals

    (Bloomberg) -- Shares in Amag Pharmaceuticals Inc. jumped after activist investor Caligan Partners said it planned to ask shareholders to replace four of the company’s directors, including Chairman Gino Santini.Caligan owns about 10.3% of the pharmaceutical company, which is launching the female libido drug Vyleesi. The New York-based hedge fund has been pushing for changes at Amag Pharma, including calling for a strategic review, cost cuts and the international expansion of its Feraheme kidney drug, according to a statement Wednesday, confirming an earlier report by Bloomberg.Shares in Amag Pharma rose 6.4% in trading Wednesday in New York to $11.96 at 9:36 a.m., giving the company a market valuation of $406 million.“We believe urgent change is needed at AMAG to reverse the sharp share price decline caused by the company’s misguided strategic priorities,” David Johnson, co-founder and managing partner at Caligan, in the statement.A representative for Amag Pharma, which is based in Waltham, Massachusetts, wasn’t immediately available for comment.Caligan, which Johnson co-founded with former Carl Icahn associate Sam Merksamer, believes Amag Pharma is undervalued and its portfolio of assets could be worth at least $30 a share, according to a presentation posted on a website dedicated to Caligan’s campaign at the company. The investment firm argues that the company’s shares have tumbled despite almost $1.4 billion spent on non-Feraheme research and development since 2012, the presentation states.Its shared had fallen 26% year to date through Tuesday’s close.Caligan is calling for a strategic review of its businesses that could result in splitting up the company, selling rights to some products or exploring partnerships, including for its women’s health segment, according to people familiar with the matter. It also contends the company’s spending is out of line with its peers, the people said, asking not to be identified because the matter is not public.Amag Pharma’s bylaws don’t allow shareholders to call a special meeting to vote for Caligan’s nominees. Instead, the hedge fund is seeking written consent from more than 50% of Amag Pharma shareholders to replace the four directors, the firm said.Caligan’s nominees are: former Boehringer Ingelheim USA Corp. Chief Executive Officer Paul Fonteyne; Alexander Wang Inc.’s ex-CEO, Lisa Gersh; Caligan’s David Johnson; and Kenneth Shea, a Guggenheim Securities LLC senior adviser. The investment firm is putting forth Fonteyne as a potential candidate for chairman, the people said.(Updates with Caligan statement starting in first paragraph; share price in paragraph three.)To contact the reporter on this story: Scott Deveau in New York at sdeveau2@bloomberg.netTo contact the editors responsible for this story: Liana Baker at lbaker75@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Thomson Reuters StreetEvents

    Edited Transcript of AMAG earnings conference call or presentation 7-Aug-19 12:00pm GMT

    Q2 2019 AMAG Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)

    AMAG Pharmaceuticals, Inc. (AMAG) announced today that Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus. Once prescribed, Vyleesi is delivered directly to a woman’s home. "In my practice I see many women who suffer from HSDD, a medical condition which impacts approximately 1 in 10 U.S. women," said Brooke Faught, DNP, WHNP-BC, NCMP, IF, Director of the Women’s Institute for Sexual Health.

  • GlobeNewswire

    AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)

    AMAG Pharmaceuticals, Inc. (AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 16,700 shares of common stock and (ii) 8,500, restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of August 19, 2019 (the grant date).

  • Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

  • Gene therapies to test FDA's approach to regulating drugs after launch, experts say
    American City Business Journals

    Gene therapies to test FDA's approach to regulating drugs after launch, experts say

    "If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.

  • TheStreet.com

    [video]New York Investment Firm Discloses 10.3% Amag Stake, May Propose Changes

    A New York investment firm disclosed a 10.3% stake in Amag Pharmaceuticals and said it would consider proposing a number of changes at the Waltham, Mass., drugmaker. Other proposals to Amag might include changes to its operations, management, board, dividend policy and strategy, among other things, the filing says.

  • Have Insiders Been Buying AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Shares?
    Simply Wall St.

    Have Insiders Been Buying AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Benzinga

    Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he doesn't like the airlines right now. It's not the right place to be. He would take a look at Delta Air Lines, Inc. (NYSE: DAL ) when ...

  • GlobeNewswire

    AMAG PHARMACEUTICALS ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(c)(4)

    AMAG Pharmaceuticals, Inc. (AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 14,500 shares of common stock and (ii) 7,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of August 12, 2019 (the grant date).

  • Why AMAG Pharmaceuticals Stock Jumped Today
    Motley Fool

    Why AMAG Pharmaceuticals Stock Jumped Today

    It continues to enjoy a strong rebound after a sell-off last week that investors seem to think was overdone.

  • AMAG Pharmaceuticals Inc (AMAG) Q2 2019 Earnings Call Transcript
    Motley Fool

    AMAG Pharmaceuticals Inc (AMAG) Q2 2019 Earnings Call Transcript

    AMAG earnings call for the period ending June 30, 2019.

  • AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
    Zacks

    AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

    AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

  • What's Behind AMAG Pharmaceuticals' Horrible Q2 Results
    Motley Fool

    What's Behind AMAG Pharmaceuticals' Horrible Q2 Results

    The drugmaker exited a key market, causing its top and bottom lines to tank in the second quarter.

  • AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates

    AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -93.94% and -15.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update

    Promoted products achieved sequential and year-over-year revenue and market share growth 2019 financial guidance lowered: exiting Makena.

  • Reuters

    UPDATE 1-Amag's female libido injectable therapy to sell at $899

    Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD). It will compete with Sprout Pharmaceuticals' Addyi, a once-daily pill. "It's not a one size fits all solution ... There is no ideal desire," Dr. Julie Krop, Amag's chief medical officer, told Reuters.

  • Reuters

    Amag's female libido injectable therapy to sell at $899

    It will compete with Sprout Pharmaceuticals' Addyi, a once-daily pill. "It's not a one size fits all solution ... There is no ideal desire," Dr. Julie Krop, Amag's chief medical officer, told Reuters.

  • AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    AMAG Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, August 7, 2019 at 8:00 a.m. ET

    WALTHAM, Mass., July 29, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2019 financial results will be released on Wednesday, August.